#07 - Deep Dive: Lp(a) — what every doctor, and the 10-20% of the population at risk, needs to know

Episode Summary

Executive Summary: Peter Attia and Bob Kaplan unpack lipoprotein(a) [LP(a)]—what it is, why it matters, how it differs from LDL, how it is measured, and why it raises risk for atherosclerosis, aortic stenosis, and venous thrombosis. They emphasize that LP(a) is largely genetic, poorly modified by lifestyle, and best assessed by particle number when available, while current and emerging therapies include statins for LDL control, PCSK9 inhibitors, niacin in select cases, and antisense oligonucleotides on the horizon.

Main Topics: What lipoproteins are and why LDL matters (Priority: 5/5): The discussion begins with a primer on cholesterol transport, explaining that cholesterol must be packaged in lipoproteins to circulate in blood, and that LDL particle number is more predictive of atherosclerotic risk than LDL-C alone. LP(a) structure and genetics (Priority: 5/5): LP(a) is described as an LDL particle with apolipoprotein(a) covalently attached to apoB via a disulfide bond. Its kringle repeat structure, especially kringle 4 type 2 variability, drives major differences in mass and particle number across individuals. How LP(a) is measured (Priority: 5/5): The speakers compare LP(a) mass, LP(a)-cholesterol, and LP(a) particle number, arguing that particle number is the most clinically useful measure because mass is confounded by variable apo(a) size and molecular weight. Clinical risks linked to elevated LP(a) (Priority: 5/5): Elevated LP(a) is associated with increased risk of atherosclerosis, aortic stenosis, and venous thromboembolism, with the aortic valve and vascular inflammation highlighted as key disease pathways. Treatment options and limitations (Priority: 5/5): Current management focuses on lowering overall apoB/LDL risk with statins and sometimes PCSK9 inhibitors; niacin and apheresis are discussed as older or niche options, while antisense oligonucleotides represent the most promising LP(a)-specific therapy. Lifestyle, inflammation, and special cases (Priority: 4/5): LP(a) appears minimally responsive to diet or exercise, unlike triglycerides or LDL in some people. The conversation also covers oxidized phospholipids, inflammatory markers, and why some ketogenic diets can markedly raise LDL-related risk markers.

Key Arguments: LDL-C is an incomplete marker; LDL particle number and apoB better reflect atherogenic burden. LP(a) is essentially an LDL particle with apo(a) attached, and apo(a) resembles plasminogen through kringle domains. The number of LP(a) particles likely matters more than LP(a) mass because apo(a) size varies widely between people. Elevated LP(a) is strongly genetic and often present in people with premature cardiovascular disease or aortic stenosis. LP(a) contributes to disease through atherosclerosis, calcific aortic stenosis, and prothrombotic effects. Statins are used to lower apoB/LDL risk, not LP(a) directly; they may leave LP(a) unchanged or even raise it in some studies. PCSK9 inhibitors can lower LP(a) by roughly 30% and sometimes more, likely by affecting multiple clearance pathways. Niacin can lower LP(a) and LDL-related markers, but outcome data are controversial and its role remains debated. Lifestyle changes have limited effect on LP(a), unlike triglycerides, which are highly diet-responsive. Antisense oligonucleotides may directly suppress apo(a) synthesis and could clarify whether lowering LP(a) improves outcomes.

Data Points: Audience vote for topic: 80% - Twitter poll favored LP(a) over hormone replacement therapy for the solo episode topic. Estimated prevalence of elevated LP(a): 1 in 5 to 1 in 10 people - Attia estimates a substantial fraction of the population carries elevated LP(a), with higher prevalence in some groups. Normal LP(a) particle number target: <50 nmol/L - Attia says this is the preferred threshold for LP(a) particle number. Gray zone LP(a) particle number: 50-100 nmol/L - Intermediate range where risk interpretation is less clear. High LP(a) particle number: >100 to >125 nmol/L - Levels that prompt concern in clinical practice. Highest LP(a) particle number seen: ~650-700 nmol/L - Attia reports the highest patient values he has encountered. LP(a) mass normal threshold, US: <30 mg/dL - U.S. lab definition cited during discussion. LP(a) mass normal threshold, European Atherosclerotic Society: <50 mg/dL - European threshold cited as a broader normal cutoff. Coverage threshold for apheresis in UK/Germany: >60 mg/dL - Mentioned as a level that can qualify for state-covered apheresis. PCSK9 inhibitor effect on LP(a): ~30% reduction, sometimes up to 50% - Observed in practice and discussed as a meaningful but incomplete reduction. Niacin effect on LP(a): ~one-third reduction - Described as a historical therapy that can lower LP(a) modestly. Aortic stenosis hazard ratio: ~2 to 4 - Epidemiologic association between elevated LP(a) and aortic stenosis. Venous thromboembolism hazard ratio: ~3 - Association between elevated LP(a) and VTE risk. Atherosclerosis odds ratio / risk increase: ~2 to 4; about 60% increase at high levels - Risk rises with higher LP(a), with a dose-response pattern described. ASO effect on LP(a): ~70% to 99% reduction - Emerging antisense oligonucleotide therapies may nearly eliminate LP(a) in some patients. ICD-10 code timing: 3 days before recording - Attia notes a new ICD-10 code for elevated LP(a) had just been issued. Family history screening age: MACE before age 60 - Used as a practical definition of premature cardiovascular disease.

Pivotal Quotes: "“The point I want to make is that you can't traffic or move around cholesterol in the bloodstream because blood approximates water.”" — Peter Attia: Explaining why cholesterol must be packaged in lipoproteins like LDL and HDL. "“LP little a is just an LDL with an ApoA on it.”" — Bob Kaplan: A simplified description of LP(a) structure during the measurement discussion. "“The further from the shore, the deeper the water.”" — Bob Kaplan: Closing reflection on how deeper study of LP(a) reveals more complexity and uncertainty.

Implications: Listeners should know their LP(a), especially with family history or premature disease. Clinicians should treat it as a meaningful inherited risk marker, screen for aortic stenosis, and focus on apoB/LDL lowering while awaiting outcome data from LP(a)-specific therapies.